Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan · Delayed Price · Currency is JPY

1,068.00

+17.00 (1.62%)

Aug 27, 2026, 12:44 PM JST

122.96% (1Y)

Market Cap	9.79B +120.3%
Revenue (ttm)	1.08B +13.5%
Net Income	369.00M +43.0%
EPS	39.62 +43.0%
Shares Out	9.31M
PE Ratio	26.53
Forward PE	n/a
Dividend	7.50 (0.73%)
Ex-Dividend Date	Mar 30, 2026

Volume	72,000
Open	1,075.00
Previous Close	1,051.00
Day's Range	1,055.00 - 1,080.00
52-Week Range	464.00 - 3,820.00
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TYO:4570

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtrat... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1982

Employees 54

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4570

Full Company Profile

Financial Performance

In fiscal year 2026, TYO:4570's revenue was 1.00 billion, an increase of 3.61% compared to the previous year's 969.00 million. Earnings were 329.00 million, an increase of 32.13%.

Financial Statements